Clear guiding material - List of Manufacturers, Suppliers, Companies and Products | IPROS GMS

[Patent Avoidance / Safety Label] NMN derivatives that comply with the Pharmaceutical and Medical Device Act and labeling rules.

"Pentide-NMN," which does not infringe on prior formulation patents for NMN, has obtained a formal display name and can be safely and securely commercialized.

When incorporating NMN (Nicotinamide Mononucleotide) into cosmetics in Japan, there are existing patents for incorporation in the range of 0.001% to 10%. Therefore, using regular NMN powder directly poses a risk of patent infringement. "Pentide-NMN" is a new ingredient derived from the precursor of NMN, and its different chemical structure does not infringe on existing NMN incorporation patents. The INCI name (Dihydroniacinamide Riboside Acetyl Tri-t-Butyl Tryptophanate) and the full ingredient display name "Dihydroniacinamide Riboside Acetyl Tri-Butyl Tryptophan" have been officially obtained. You can safely commercialize products under the concepts of "NMN derivatives" and "skin longevity" while completely avoiding legal risks. 【Features】 ■ Does not infringe on existing NMN incorporation patents (0.001-10%) ■ INCI name and full ingredient display name officially obtained ■ Compliant with pharmaceutical and labeling regulations for commercialization ■ A reliable NMN concept that avoids patent risks *For more details, please check by downloading the catalog.